Intracellular cGMP increase is not involved in thyroid cancer cell death.

ABSTRACT:

Introduction

Type 5 phosphodiesterase (PDE5) inhibitors (PDE5i) lead to intracellular cyclic-guanosine monophosphate (cGMP) increase and are used for clinical treatment of erectile dysfunction. Studies found that cGMP may up/downregulate the growth of certain endocrine tumor cells, suggesting that PDE5i could impact cancer risk.

Aim

We evaluated if PDE5i may modulate thyroid cancer cell growth in vitro.

Materials and methods

We used malignant (K1) and benign (Nthy-ori 3-1) thyroid cell lines, as well as the COS7 cells as a reference model. Cells were treated 0-24 h with the PDE5i vardenafil or the cGMP analog 8-br-cGMP (nM-μM range). cGMP levels and caspase 3 cleavage were evaluated by BRET, in cGMP or caspase 3 biosensor-expressing cells. Phosphorylation of the proli

SUBMITTER: Alessandro S 

PROVIDER: S-EPMC10062617 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature